Investigating a new genetic variant linked to preeclampsia
Official title: Novel NF-kB variant in preeclampsia
Funded at University of Colorado Denver · NIH-10809507 · Data updated 2026-11-12
This study is looking at a new version of a gene that might play a role in preeclampsia, a serious condition during pregnancy, by using advanced gene-editing techniques and focusing on women in Bolivia, to see how it affects blood flow and the health of the placenta.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $234,000 |
| NIH project number | 1R21HD111905-01A1 |
| Project ID | NIH-10809507 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pregnant women, particularly those from high-altitude regions or with a family history of preeclampsia.
✕Less likely to help
Patients who are not pregnant or those without a history of preeclampsia may not benefit from this research.
What this research studies
This research focuses on understanding how a novel variant of the NF-kB gene may contribute to preeclampsia, a serious pregnancy complication. By using CRISPR gene-editing techniques and studying a population in Bolivia, where preeclampsia is more common, the researchers aim to uncover the role of this genetic variant in inflammatory responses during pregnancy. The study will involve physiological assessments to determine how this variant affects blood flow and placental health, which are critical for a healthy pregnancy.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of preeclampsia, potentially improving outcomes for mothers and infants.
How similar studies have gone: Previous research has shown promising results in understanding genetic factors in preeclampsia, but this specific approach using CRISPR is relatively novel.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Julian, Colleen Glyde — University of Colorado Denver
- Study coordinator: Julian, Colleen Glyde
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
-
Folate Receptor Beta and its Role in Preeclampsia
This study explores how a protein called folate receptor beta on placental immune cells may drive or worsen preeclampsia in pregnancy, with hopes of finding new ways to prevent or treat the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.